NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
KRAS pathways are frequently upregulated in cancers bearing KRAS mutations or by other signaling modifications. Also, resistance to KRAS G12C inhibitors and other KRAS/RAF/MEK pathway drugs is ...
Cancer Res (2023) 83 (7_Supplement): 1142.
Cancer Res (2025) 85 (8_Supplement_1): 372.
Mol Cancer Ther (2023) 22 (12_Supplement): A085.
Background: KRAS is a key mediator of the RAS/MAPK signaling cascade and promotes cellular growth and proliferation. It is the most frequently mutated oncogene in cancer, and KRAS G12C mutations occur ...
Cancer Res (2024) 84 (3_Supplement_2): PR014.
Abstract. A key barrier to effective immunotherapy for cancer is the immunosuppressive tumor microenvironment (TME) characterized by infiltrating regulatory T cells (Tregs) and myeloid-derived ...
Abstract. Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) directed against CD30. It consists of an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a ...
AbstractPurpose:. Accurate assessment of invasiveness in pediatric thyroid carcinomas is essential to prevent unnecessary surgery and avoid surgery-associated complications. DNA methylation, a proven ...
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex Open Access Linjie Yuan; Wenzhi Ji; Brendan G. Dwyer; Joey Lu; Jing Bian; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results